Early Screening

Early screening of antimicrobials can be performed in our Galleria mellonella (wax moth larvae) model, to provide information on compound toxicity and efficacy and help design optimal dosing regimens, including the assessment of combination therapies, prior to use in a murine model of infectious disease. Use of bioluminescent bacteria enables the infection to be tracked using GloMAX and IVIS technology.

Tell Us How We Can Support Your Anti-Infective Program

Benefits of Galleria mellonella Model

  • Possess an innate immune system comprising of cellular and humoral responses, comparable to the mammalian system
  • Infections performed at 37oC
  • Cost effective, pre-screening in vivo model
  • Uses:
    • Microbial pathogenesis studies e.g. assessment of virulence differences between strains and virulence gene identification
    • Pre-clinical screening for efficacy and toxicity of novel compounds
    • PK/PD analysis

Study Endpoints

  • Survival
  • Bacterial load – CFU and IVIS
  • Melanisation score

Survival following treatment with increasing doses of Vancomycinin in a lethal Staphylococcus aureus model
Bioluminescent bacteria can be used in our model system to give an estimate of bacterial load within infected larvae, in-life, over the course of the infection. Survival data can also be provided to show effect of increasing doses of antimicrobial as shown here with vancomycin. Assessment of bacterial load at termination confirms efficacy.